ALTEOGEN Inc is a biopharmaceutical company that focuses on the development and commercialization of novel biologics such as Antibody-drug conjugates, biobetters, and biosimilars. ALTEOGEN is actively involved in the research and development of the next generation of biobetters and biosimilars, with a focus on sustainable bioveter, antimicrobial additives therapeutics, and the antibiosimiller sector. The company is also developing ALT-L2, a biosimilar of Herceptin, and utilizing the NexMab ADC technology to develop targeting medication for Ovarian Cancer Antibiotic-Medium Composite Therapy. Additionally, ALTEOGEN has signed a license-out agreement for its "ALT-B4" SC transformation platform technology.
Headquarters
305, Daejeon Bio Venture Town, 62, Yuseong-Daero 1628Beon-G, Yuseong-Gu, Daejeon
Daejeon; Daejeon;
Contact Details: Purchase the Alteogen Inc. report to view the information.
Website: http://www.alteogen.com
EMIS company profiles are part of a larger information service which combines company, industry and country data and analysis for over 145 emerging markets.
Request a demo of the EMIS serviceTo view more information, Request a demonstration of the EMIS service